New drug cocktail aims to tackle returning myeloma

NCT ID NCT06785415

Recruiting now Disease control Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a combination of four drugs—iberdomide, daratumumab, elotuzumab, and dexamethasone—in people whose multiple myeloma has come back after treatment. The study has two phases: first, finding the safest dose of iberdomide, and second, seeing how well the combo works at shrinking tumors. About 37 participants will be enrolled, all of whom have had up to three prior treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: iberdomide, daratumumab, elotuzumab, and dexamethasone
What this could lead to: If it works, this could offer a new treatment option for people whose multiple myeloma has returned after prior therapies.
What could go wrong: This is an early-phase trial with only 37 participants, so results may not apply broadly. The combination may cause significant side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT MULTIPLE MYELOMA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Mayo Clinic in Rochester
RECRUITING

Rochester, Minnesota, 55905, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.